Alan A. Musso
Independent DirectorMr. Alan A. Musso, C.P.A., C.M.A., serves as an Independent Director at Rein Therapeutics Inc. (formerly known as Aileron Therapeutics, Inc.) since October 31, 2023. He is Independent Director at Research Alliance Corporation IV since July 10, 2026. He is Chief Financial Officer of Fulcrum Therapeutics, Inc. since August 09, 2023 and serves as principal accounting officer since August 7, 2026 and serves as its Treasurer. He served as the Chief Financial Officer of ReViral Ltd since October 2019. He served as Chief Financial Officer at OS Therapies Inc since March 01, 2023. Mr. Musso served as Chief Financial Officer at Peloton Therapeutics, Inc. since September 04, 2018 until September 2019. He served as an independent consultant in the biotech industry from October 2022 through February 2023 Mr. Musso served as the Chief Financial Officer and Treasurer at Bellicum Pharmaceuticals, Inc. since November 2014 until August 2018. Mr. Musso has many years of biotechnology and pharmaceutical industry experience in both large and emerging growth companies, including capital raising, corporate partnering, finance, strategy and the financial stewardship of publicly-traded companies. He served as the Chief Financial Officer, Senior Vice President of Finance & Administration, Treasurer and Assistant Secretary at Catalyst Biosciences, Inc. until 2014. He served as the Chief Financial Officer and Treasurer of Targacept, Inc. from February 2002 to November 18, 2014 and its Senior Vice President of Finance & Administration from March 2010 to November 18, 2014. He served as an Assistant Secretary of Targacept, Inc. since June 2007. He served as Principal Accounting Officer of Targacept, Inc. He served as Vice President of Targacept, Inc. from February 2002 to March 2010. He served as Secretary of Targacept, Inc. since February 2002. He served as the Chief Financial Officer of Cato Research Ltd. He served as the Chief Financial Officer and Vice President of Osiris Therapeutics Inc. from February 2001 to February 2002. He served as the Chief Financial Officer of Cato Research & Cato Holding Company from April 1997 to February 2001. He served as Director of Finance and Accounting of Duramed Pharmaceuticals, Inc. from January 1995 to March 1997. He served as the Chief Financial Officer of Vascular Genetics Inc. from October 1997 to February 2000. He worked at Pfizer Inc. from April 1989 to December 1994, first as a Senior Auditor and then as a General Accounting Manager for one of Pfizers manufacturing facilities. He is a Certified Public Accountant and a Certified Management Accountant. Mr. Musso received a B.S. in Accounting from Saint Mary's College of California and a Master of International Management degree from Thunderbird School of Global Management.
Positions
- Company NameResearch Alliance Corporation IVStock CodeRACDPositionIndependent Director
- Company NameFulcrum Therapeutics, Inc.Stock CodeFULCPositionCFO, Treasurer & Principal Accounting OfficerColleagues
- ACAlexander C. SapirCEO, President & Director
- KHKathryn HavilandIndependent Chair of the Board
- CGCurtis G. OltmansChief Legal Officer, Head of External Affairs & Corporate Secretary
- BEBradley E. BernsteinFounder
- MRMichael R. GreenFounder
- JAJames Arthur GeraghtyIndependent Director
- KDKatina DortonIndependent Director
- RKRachel K. KingIndependent Director
- Company NameRein Therapeutics Inc.Stock CodeRNTXPositionIndependent DirectorColleagues
- JBJames Brian WindsorCEO, President & Director
- JHJosef H. von RickenbachIndependent Chairman
- TMTimothy M. CunninghamInterim CFO & Principal Accounting Officer
- CMCory M. HogaboamChief Scientific Officer
- JFJennifer FaigleCounsel
- RCRon ChenVP of Finance and Corporate Controller
- RJReinhard J. AmbrosIndependent Lead Director
- AAAlan A. MussoIndependent Director
- WCWilliam Carl FaireyIndependent Director
